Recent quotes:

Efficacy, Safety, and Tolerability of Three Doses of Sulthiame in Patients With Obstructive Sleep Apnea. A Randomized, Double-blind, Placebo Controlled, Dose-ranging Study (STM-042/K) | B14. LATE BREAKING ABSTRACTS: SCIENCE THAT WILL IMPACT CLINICAL CARE

Empty heading Efficacy, Safety, and Tolerability of Three Doses of Sulthiame in Patients With Obstructive Sleep Apnea. A Randomized, Double-blind, Placebo Controlled, Dose-ranging Study (STM-042/K)

Epilepsy Drug Shows Promise in Reducing Obstructive Sleep Apnea Symptoms

Patients who took the carbonic anhydrase inhibitor experienced fewer breathing interruptions during sleep and improved oxygen levels. The apnea-hypopnea index (AHI3a), which tracks the frequency of respiratory pauses, decreased by 17.8% in those on the lowest dose (100 mg), 34.8% on the medium dose (200 mg), and 39.9% on the highest dose (300 mg). When using the AHI4 measure for when oxygen levels were more severely affected, the reduction in respiratory pauses was nearly 50%. Patients also reported feeling less daytime sleepiness while on the medication. These findings are based on a double-blind, randomized, placebo-controlled trial presented at the ERS Congress by Jan Hedner, MD, PhD, professor of respiratory medicine at Sahlgrenska University Hospital and the University of Gothenburg in Sweden and lead author of the study.2